EFM
ALXN

E Fund Management’s Alexion Pharmaceuticals ALXN Stock Holding History

E Fund Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		$636K Buy
+4,159
New +$643K 0.05% 115

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

E Fund Management's ALXN Position: Q1 2021 in Review

E Fund Management opened a new position in Alexion Pharmaceuticals (ALXN) in Q1 2021: 4,159 shares worth $636K. The stake represents 0.05% of the portfolio and ranks #115 among its holdings.

752 funds tracked by Wall St. Rank hold ALXN as of Q1 2021.

  • E Fund Management held 4,159 shares of Alexion Pharmaceuticals worth $636K as of Q1 2021.
  • Alexion Pharmaceuticals was a new E Fund Management position in Q1 2021.
  • Alexion Pharmaceuticals made up 0.05% of E Fund Management's portfolio in Q1 2021, its #115 holding.
  • 752 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2021.

Based on E Fund Management's 13F filing for Q1 2021, filed 12 May 2021.